1. Home
  2. GH vs EPR Comparison

GH vs EPR Comparison

Compare GH & EPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$103.60

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Logo EPR Properties

EPR

EPR Properties

HOLD

Current Price

$52.35

Market Cap

4.4B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
GH
EPR
Founded
2011
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
4.4B
IPO Year
2018
1997

Fundamental Metrics

Financial Performance
Metric
GH
EPR
Price
$103.60
$52.35
Analyst Decision
Strong Buy
Buy
Analyst Count
21
11
Target Price
$79.19
$57.06
AVG Volume (30 Days)
2.9M
588.8K
Earning Date
10-29-2025
10-29-2025
Dividend Yield
N/A
6.76%
EPS Growth
N/A
N/A
EPS
N/A
2.29
Revenue
$902,569,000.00
$707,150,000.00
Revenue This Year
$34.72
$5.11
Revenue Next Year
$26.46
$2.70
P/E Ratio
N/A
$22.91
Revenue Growth
30.38
3.73
52 Week Low
$29.91
$41.75
52 Week High
$112.43
$61.24

Technical Indicators

Market Signals
Indicator
GH
EPR
Relative Strength Index (RSI) 66.40 53.25
Support Level $98.23 $51.76
Resistance Level $112.43 $52.94
Average True Range (ATR) 5.44 0.84
MACD -0.54 0.34
Stochastic Oscillator 64.46 77.42

Price Performance

Historical Comparison
GH
EPR

About GH Guardant Health Inc.

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About EPR EPR Properties

EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The Company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.

Share on Social Networks: